MOLN News

The IPO market was in full swing this past week as 16 IPOs and six SPACs went public. The IPO pipeline cooled down with just one IPO and nine SPACs submitting initial filings. The largest deal of the week, Lyell Immunopharma (LYEL) priced at the midpoint to raise $425 million at a $4.7 billion market cap. The company is using proprietary genetic and...read more

Molecular Partners, a Swiss biotech developing engineered protein therapies for COVID-19 and cancers, raised $64 million by offering 3 million ADSs at $21.25, below the as-converted last close of its shares on the SIX Swiss Exchange ($23.53). Molecular Partners states that its proprietary DARPin molecular platform allows it to create product candidates with multiple mechanisms of...read more

Updated Monday, 6/14. 15 IPOs are currently slated to raise $2.5 billion in the week ahead, led by a preclinical biotech being valued at $4.7 billion. The largest deal of the week, Lyell Immunopharma (LYEL) plans to raise $425 million at a $4.7 billion market cap. The company is using proprietary genetic and epigenetic reprogramming to develop T...read more

Molecular Partners, a Swiss biotech developing engineered protein therapies for COVID-19 and cancers, announced terms for its IPO on Wednesday. The Zurich, Switzerland-based company plans to raise $81 million by offering 3 million ADSs at $27.14 per share, the as-converted last close of its share on the SIX Swiss Exchange (MOLN). At the proposed price, Molecular Partners would...read more